| Literature DB >> 31171831 |
Weijian Li1,2, Bo Xu3, Yuepeng Cao2, Yang Shao4, Wanke Wu1, Jun Zhou2, Xiaofang Tan1, Xiaoli Wu1, Jing Kong1, Chen Hu1, Kaipeng Xie5, Jiangping Wu6.
Abstract
Several studies assessed the association of maternal folate intake with infant asthma risk, but the findings are controversial. We performed a meta-analysis to clarify the association between maternal folate intake and infant asthma risk. PubMed and SCOPUS databases were searched for related studies published until August 2018. Fixed-effects models were applied to pool relative risks (RRs) and their corresponding 95% confidence intervals (CIs) due to the low heterogeneity. We also adopted generalized least-squares trend (GLST) estimation for the dose-response analysis. In our study, a total of 10 studies with maternal folate intake and 5 studies with blood folate concentration were included. We found that maternal folate intake during pregnancy was significantly related to the risk of infant asthma (RR = 1.11; 95% CI = 1.06-1.17). Similar results were found for geographic region from Europe (RR = 1.08; 95% CI = 1.01-1.16) and North America (RR = 1.20; 95% CI = 1.11-1.30) in subgroup analyses. Meanwhile, the dose-response analysis showed a linear relationship between maternal folic acid intake during pregnancy and infant asthma risk. This meta-analysis indicates that maternal folate intake during pregnancy could increase infant asthma risk. Therefore, the adverse effect of folic acid on infant asthma should not be ignored when it is supplemented during pregnancy to prevent birth defects.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31171831 PMCID: PMC6554315 DOI: 10.1038/s41598-019-44794-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flowchart of the search strategy and study selection process.
Baseline characteristics of individual studies on maternal folate intake and infant asthma.
| Author, | Region | Study type | Sample | Mothers’ age | Sources of folic acid intake | Exposure period | Age at visit (years) | Assessments of outcomes | Adjustment for covariates | Study |
|---|---|---|---|---|---|---|---|---|---|---|
Trivedi M. K. 2018 | United States | Cohort study | 1,279 | 32.2 | Foods and supplements | First trimesters, second trimester | 7.9 | Based on the validated instruments from the ISAAC* | Maternal age, maternal history of asthma, household income, child race/ethnicity, gestational age, breastfeeding duration, and age at mid-childhood visit | 7 |
| den Dekker H. T. | Netherlands | Cohort study | 5,653 | 31 | Folic acid supplementation use | Preconception, before 18 weeks of gestation | 10 | Physician ever having diagnosed asthma or the use of inhalant medication in the past 12 months | Maternal age, maternal history of asthma, child race/ethnicity, gestational age, body mass index at intake, parity, educational level, smoking or alcohol use | 7 |
Parr C. L. 2017 | Norwegian | Cohort study | 39,846 | 30.0 | Foods and supplements | 18 and 22 weeks of pregnancy | 7 | Use at least two asthma medications or maternal report of the child ever having physician-verified asthma plus either asthma symptoms or asthma medication use in the past year | Parity, maternal education, prepregnancy body mass index, maternal history of atopy, maternal smoking in pregnancy, use of cod liver oil or other dietary supplements, and maternal energy intake in pregnancy | 7 |
| Veeranki S. P. | United States | Cohort study | 104,428 | 22 | Folic acid-containing supplements | First trimester only, after first trimester, first trimester and beyond | 4.5–6 | Using a previously validated algorithm that uses asthma-specific healthcare visits and asthma-specific medication use | Infant gender, estimated gestational age, birth weight, other living siblings, maternal race, region of residence, pregnancy year, marital status, age at delivery, level of education, smoking during pregnancy and adequacy of prenatal care | 7 |
| Zetstra-van der Woude P. A. | Netherlands | Cohort study | 35,604 | 15–50 | Folic acid supplements | During pregnancy. | Childhood | Use of asthma medication | Maternal age, dispensation of benzodiazepines during pregnancy, and maternal dispensation of asthma medication | 8 |
| Bekkers M. B. | Netherlands | Cohort study | 3786 | 30.5 | Folic acid supplements | During pregnancy. | 1–8 | At least one attack of wheeze, and/or at least one attack of dyspnoea, and/or prescription of inhalation steroids for respiratory or lung problems by a medical doctor | Maternal education, maternal allergy, maternal smoking during pregnancy and number of older siblings | 6 |
| Martinussen M. P. | USA | Cohort study | 1499 | <25: 22.75%; 25–35: 58.97%; >35: 18.28% | Food and supplements | First trimester, 1 month before conception | 6 | Mothers’ reports of physician-diagnosed asthma or wheezing or whistling symptoms ever in the last 12 months | Household annual income, maternal marital status, and physician diagnosed maternal asthma | 6 |
| Magdelijns F. J. | Netherlands | Cohort study | 2640 | NA | Folic acid supplements | 4 weeks before until 8 weeks after conception | 6–7 | Physician-diagnosed asthma with clinical symptoms and/or the use of asthma medication ever in the last 12 months | Maternal antibiotic use during pregnancy, maternal smoking and alcohol consumption during pregnancy, mode and place of delivery, birth weight, infant gender, treatment with antibiotics during the first 6 months of life, breastfeeding during the first 2 years of life, exposure to domestic animals during pregnancy and the first 2 years of life, exposure to environmental tobacco smoke in the first 6 to 7 years of life, siblings, family history, recruitment group, maternal education level, day care, and other supplement use during pregnancy | 7 |
| Whitrow M. J. | Australia | Cohort study | 423 | 30.5 | Food and supplements | Prepregnancy; <16 weeks; 30–34 weeks | 5.5 | Physician-diagnosed asthma or current asthma | Maternal education, maternal age, parity, gestational age, maternal asthma status, and breastfeeding | 6 |
| Granell R. | UK | Cohort study | 6090 | 28.4 | Food and supplements | 18 and 32 weeks of pregnancy. | 7.5 | Physician diagnosed asthma and wheezing during the past 12 months | Gender, maternal history of asthma or allergy, maternal dietary folate intake at 18 or 32 weeks gestation, exposure to prenatal and postnatal maternal smoking and maternal education | 6 |
*ISAAC: the International Study of Asthma and Allergies in Childhood.
#Quality assessment was performed with the NOS.
Baseline characteristics of individual studies on blood folate concentration and infant asthma.
| Author | Year | Region | N | RR (95%CI) | Sample type | Adjustment for covariates |
|---|---|---|---|---|---|---|
| den Dekker H. T. | 2018 | Netherlands | 276 | 0.93 (0.79–1.09) | Serum | Maternal age and BMI at intake, parity, history of asthma or atopy, educational level, smoking or alcohol use during pregnancy, child’s gestational age at birth, birthweight and ethnicity |
| Parr C. L. | 2017 | Norway | 2,681 | 0.97 (0.54–1.76) | Plasma | Maternal age at delivery, parity maternal education, prepregnancy BMI, maternal history of atopy, maternal smoking in pregnancy, use of cod liver oil and other dietary supplements in pregnancy, and gestational week of sample collection |
| Magdelijns F. J. | 2011 | Netherlands | 2640 | 0.31 (0.09–1.10) | In erythrocytes | Maternal antibiotic use during pregnancy, maternal smoking during pregnancy, maternal alcohol consumption during pregnancy, mode and place of delivery, birth weight, gender of the child, treatment with antibiotics during the first 6 months of life, breastfeeding duration, exposure to domestic animals during pregnancy and the first 2 years of life, exposure to environmental tobacco smoke in the first 6 to 7 years of life, siblings, family history of atopy, recruitment group, maternal education level, day care, and multivitamin or other supplement use during pregnancy. |
| van der Valk R. J. | 2013 | Netherlands | 2,001 | 1.02 (0.83–1.25) | Cord blood | Maternal age, BMI, educational level at intake, history of maternal atopy or asthma, smoking and folic acid supplement use during pregnancy, parity and children’s sex, gestational age and birth weight |
| Håberg S. E. | 2011 | Norway | 1962 | 1.66 (1.16–2.37) | Plasma | Maternal educational level, maternal age, parity, maternal atopy, maternal BMI, maternal smoking in pregnancy and maternal smoking at age 3 years, supplement use at age 3 years |
Figure 2Forest plot showing pooled relative risks and corresponding 95% CIs of infant asthma according to maternal folate intake. The grey squares indicate study-specific relative risks, the horizontal lines represent the 95% CI, and the size of each square is proportional to its weight in the analysis. The diamond represents the summary relative risk estimate with its 95% CI.
Figure 3Forest plot showing pooled relative risks and corresponding 95% CIs of infant asthma according to blood folate concentration.
Results of the subgroup analysis for the association between maternal folate intake and infant asthma risk.
| Variables | N | RR (95%CI)a | Heterogeneity testb | ||||
|---|---|---|---|---|---|---|---|
| Estimate | 95% CI | χ2 |
| I2c | |||
| All studies | 1.11 | 1.06 | 1.17 | 15.16 | 0.087 | 40.60% | |
| Geographic region | |||||||
| Europe | 7 | 7.00 | 0.321 | 14.23% | |||
| North America | 2 | 0.01 | 0.927 | 0.00% | |||
| Australia | 1 | 0.92 | 0.77 | 1.11 | — | — | — |
| Publication year | |||||||
| <2013 | 5 | 1.03 | 0.94 | 1.12 | 3.29 | 0.510 | 0.00% |
| ≥2013 | 5 | 7.69 | 0.104 | 48.00% | |||
| Sample size | |||||||
| <5000 | 5 | 1.00 | 0.91 | 1.10 | 2.96 | 0.565 | 0.00% |
| ≥5000 | 5 | 5.63 | 0.228 | 29.00% | |||
| Quality score | |||||||
| <7 | 4 | 1.02 | 0.94 | 1.12 | 2.87 | 0.413 | 0.00% |
| ≥7 | 6 | 7.78 | 0.169 | 35.70% | |||
| Folate source | |||||||
| Totald | 5 | 1.09 | 0.99 | 1.21 | 7.67 | 0.104 | 47.80% |
| Supplement | 5 | 7.39 | 0.117 | 45.90% | |||
| Exposure period | |||||||
| Early pregnancy | 7 | 9.37 | 0.154 | 36.0% | |||
| Others | 3 | 1.08 | 0.97 | 1.20 | 4.01 | 0.135 | 50.1% |
| Assessment method | |||||||
| FFQ | 5 | 1.09 | 0.99 | 1.21 | 7.67 | 0.104 | 47.80% |
| Others | 5 | 7.39 | 0.117 | 45.90% | |||
| Adjustments maternal smoking | |||||||
| Yes | 6 | 5.71 | 0.335 | 12.50% | |||
| No | 4 | 1.00 | 0.91 | 1.10 | 2.42 | 0.491 | 0.00% |
| Adjustments maternal allergy | |||||||
| Yes | 8 | 1.06 | 1.00 | 1.13 | 9.61 | 0.212 | 27.20% |
| No | 2 | 0.03 | 0.863 | 0.00% | |||
| Adjustments maternal education | |||||||
| Yes | 7 | 11.23 | 0.081 | 46.60% | |||
| No | 3 | 1.03 | 0.92 | 1.15 | 1.42 | 0.491 | 0.00% |
RR: relative risk FFQ: Food Frequency Questionaire.
aRR (95% Cl) indicates pooled estimates of study-specific RRs with corresponding 95% CIs.
bHeterogeneity test indicates the heterogeneity of subgroup analyses.
cI2 shows the degree of heterogeneity among studies.
dTotal folic acid intake was from diet and supplements
Figure 4Dose-response relationship between maternal folate intake and infant asthma. The solid line and the dash line represent the estimated relative risks and corresponding 95% confidence intervals. Folic acid intake was modeled with a linear trend (P-value for non-linearity = 0.82) in a fixed-effects model.